Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $95,659,436.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Keros Therapeutics Trading Up 0.7%

Keros Therapeutics stock opened at $13.83 on Friday. The company has a market capitalization of $561.77 million, a price-to-earnings ratio of 44.61, a PEG ratio of 1.77 and a beta of 0.97. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The stock’s 50 day moving average is $15.28 and its 200-day moving average is $14.23.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same period in the prior year, the firm posted ($1.25) EPS. The company’s revenue for the quarter was up 49002.7% on a year-over-year basis. As a group, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. GAMMA Investing LLC boosted its stake in shares of Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company’s stock valued at $237,000 after purchasing an additional 2,384 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Keros Therapeutics in the 1st quarter valued at approximately $25,000. CWM LLC boosted its position in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Keros Therapeutics during the third quarter worth $47,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KROS. HC Wainwright lowered their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $30.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.